Our laboratory works on Smith-Lemli-Opitz syndrome,inborn errors of cholesterol biosynthesis and Niemann-Pick Disease, type C1. SLOS is a human autosomal recessive multiple congenital anomaly/cognitive impairment syndrome characterized by facial dysmorphology, cognitive impairment, a characteristic behavioral phenotype, growth retardation, and variable structural anomalies of the heart, lungs, brain, gastrointestinal tract, limbs, genitalia and kidneys. SLOS also has a distinct behavioral phenotype which includes self-injurious and autistic features. Biochemically, patients with SLOS have an inborn error of cholesterol biosynthesis;specifically they have a defect in the conversion of 7-dehydrocholesterol to cholesterol. However, we do not know why these children have such a variety of congenital malformations, and neurological problems. We cloned the gene encoding the 7-dehydrocholesterol reductase, and have subsequently identified mutations in this gene in more than fifty patients with Smith-Lemli-Opitz syndrome. Our laboratory continues to identify mutations in SLOS patients, and to determine residual enzymatic function in patient fibroblasts. This information is being used to establish genotype/enzymatic activity/phenotype correlations for this disorder. We have also isolated the mouse gene encoding this enzyme, and have produced multiple mouse models for this disorder. We are using these mouse models to further our understanding of how the malformations seen in this syndrome develop, and to further our understanding of the neurophysiological basis of the neurological problems associated with this syndrome. A hypomorphic mouse model of SLOS has also been developed. This mouse model is being used to investigate therapeutic interventions including dietary cholesterol supplementation, simvastatin therapy, and gene therapy. Our SLOS mouse models continue to be used to understand the pathophysiological processes that underlie the birth defects and clinical problems found in SLOS. Various biochemical, molecular, and proteomic approaches are being utilized to investigate these issues. These mouse models are being used to test various prenatal and postnatal therapeutic interventions. One of the most intriguing aspects of SLOS is the distinct behavioral phenotype. Most patients with SLOS have autistic features. We are currently working in collaboration with groups from Kennedy Krieger Institute in Baltimore and NHGRI to further analyze this association and to study whether abnormalities of cholesterol metabolism contribute to autism in general. In addition to SLOS, we have developed mouse models of lathosterolosis, desmosterolosis, and HEM dysplasia. These human syndromes all involve defects in cholesterol synthesis. We are using these mouse models to further our understanding of the biological processes which cause the birth defects found in these syndromes. Our laboratory also works to understnad the pathological processes underlying Niemann-Pick disease, type C1 (NPC1). NPC1 is a genetic disorder due to impaired intracellular cholesterol and lipid transport. Patients with NPC1 die due to a progressive neurological disorder. The laboratory is applying proteomic techniques to understand pathophysiological processes underlying clinical problems found in NPC and to identify biomarkers that can be used in future clincal trials. The basic science work done in this laboratory supports and complements the clinical work also being performed by this Section. The combination of basic science and clinical science work in one Section facilitates the rapid translation of findings from the bench to the bedside and vice versa.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Ottinger, Elizabeth A; Kao, Mark L; Carrillo-Carrasco, Nuria et al. (2014) Collaborative development of 2-hydroxypropyl-*-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem 14:330-9
Sparks, S E; Wassif, C A; Goodwin, H et al. (2014) Decreased cerebral spinal fluid neurotransmitter levels in Smith-Lemli-Opitz syndrome. J Inherit Metab Dis 37:415-20
Hung, Ya Hui; Faux, Noel G; Killilea, David W et al. (2014) Altered transition metal homeostasis in Niemann-Pick disease, type C1. Metallomics 6:542-53
King, Kelly A; Gordon-Salant, Sandra; Yanjanin, Nicole et al. (2014) Auditory phenotype of Niemann-Pick disease, type C1. Ear Hear 35:110-7
te Vruchte, Danielle; Speak, Anneliese O; Wallom, Kerri L et al. (2014) Relative acidic compartment volume as a lysosomal storage disorder-associated biomarker. J Clin Invest 124:1320-8
Tortelli, Brett; Fujiwara, Hideji; Bagel, Jessica H et al. (2014) Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1). Hum Mol Genet 23:6022-33
Schreiber, John M; Lanham, Diane C; Trescher, William H et al. (2014) Variations in EEG discharges predict ADHD severity within individual Smith-Lemli-Opitz patients. Neurology 83:151-9
Jiang, Hui; Sidhu, Rohini; Fujiwara, Hideji et al. (2014) Development and validation of sensitive LC-MS/MS assays for quantification of HP-?-CD in human plasma and CSF. J Lipid Res 55:1537-1548
Cologna, Stephanie M; Cluzeau, Celine V M; Yanjanin, Nicole M et al. (2014) Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1. J Inherit Metab Dis 37:83-92
King, Kelly A; Gordon-Salant, Sandra; Pawlowski, Karen S et al. (2014) Hearing loss is an early consequence of Npc1 gene deletion in the mouse model of Niemann-Pick disease, type C. J Assoc Res Otolaryngol 15:529-41

Showing the most recent 10 out of 16 publications